Treace Medical Concepts (NASDAQ:TMCI) reaffirmed its full-year 2026 revenue outlook after reporting a first-quarter revenue ...

The growth of the market can be attributed to the introduction of technologically advanced equipment in the healthcare sector ...

Good day, and thank you for standing by. Welcome to the Treace Medical Concepts First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being ...

Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical ...

In addition to our 3 new bunion systems, we expanded our portfolio with the addition of new SpeedPlate implants, new sterile instruments and we introduced our first biologics offerings. These ...

PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical ...

An additional 14 types of surgery are being added to the NSW government’s list of ‘same day surgery’ procedures which allow ...

An ‘InStyle’ editor’s 55-year-old mom is known as the best-dressed in every room. Shop her seven summer travel fashion finds, ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02, an investigational fast-acting oral formulation of meloxicam, for the ...

FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the ...